ARID1A and neoplasm: It suggests that other factors beyond MSI, such as the reduced tumor aneuploidy level and deregulation of ARID1A-mediated pathways, may also contribute to the increased tumor immunity in ARID1A-mutated GI cancers (Figure 5).